Raluca Ionescu-Ittu

Education

Ph.D. and M.S., epidemiology, McGill University; B.A., social work, Bucharest University

Summary of Experience

Dr. Ionescu-Ittu is a quantitative epidemiologist with expertise in comparative effectiveness methods and study designs for observational studies of drug effects. She has experience working with medical claims, chart review, and clinical trial data to study the incidence and prevalence of diseases, the risks and benefits of medications, and health resource utilization and health care costs. Her clinical areas of expertise include oncology, congenital heart disease, cardiology, and immune diseases. Dr. Ionescu-Ittu joined Analysis Group in 2012 after completing a one-year postdoctoral research program at Harvard University.

Selected Publishing

• Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study

  Future Oncology. 2019 Feb;15(4):359-370
  2019

  Tarhini A, Ghate S, Ionescu-Ittu R, Shi S, Nakasato A, Ndife B, Laliberté F, Burne R, Duh MS

  Health Care
• Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy

  Lung Cancer. May 2018;119:112-119
  2018

  Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, Ionescu-Ittu R

  Health Care
• Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center

  International Urology and Nephrology. Mar 2018;50(3):459-467
  2018

  Ruud Bosch JLH, Vekeman F, Duh MS, Neary M, Magestro M, Fortier J, Karner P, Ionescu-Ittu R, Zonnenberg BA 

  Health Care
• Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus

  PLOS ONE. Nov 15 2018; 13(11): p. e0204646
  2018

  Zonnenberg BA, Neary MP, Duh MS, Ionescu-Ittu R, Fortier J, Vekeman F

  Health Care
• Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication

  BMC Infectious Diseases, 2018 Aug 29;18(1):438
  2018

  Vekeman F, Weiss L, Aram J, Ionescu-Ittu R, Moosavi S, Xiao Y, Cheng WY, Bhak RH, Tawadrous M, Capparella MR, Montravers P, Duh MS

  Health Care
• Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy

  Current Medical Research and Opinion. 2018 Dec;34(12):2169-2176
  2018

  Ghate SR, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS

  Health Care
• Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive

  Melanoma Research, October 9, 2018
  2018

  Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberté F, Nakasato A, Duh MS

  Health Care
• Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer

  Clinical Lung Cancer. Nov 2017;18(6):640-650 e642
  2017

  Ganti AK, Hirsch FR, Wynes MW, Ravelo A, Ramalingam SS, Ionescu-Ittu R, Pivneva I, Borghaei H

  Health Care
• Overall survival in patients with glioblastoma before and after bevacizumab approval

  Current Medical Research and Opinion. May 2018;34(5):813-820
  2017

  Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm J

  Health Care
• Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma

  Melanoma Research. 2018 Dec;28(6):618-628
  

  Tarhini A, Ghate SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberté F, Nakasato A, Burne R, Duh MS

  Health Care

News

• April 16, 2018

  AMCP’s Managed Care & Specialty Pharmacy Annual Meeting to Feature New Outcomes Research from Analysis Group

  Health Care